create XmAb approach natural in can joining antibody The action. therapeutic platform. and us specifically engineering an new structure, therapeutics and thanks to By its our this is functions and Xencor's we improve Fc afternoon. Thanks, small its antibody mechanisms to making and of creating changes cytokine of performance everyone core for domain,
us The simultaneously, nearly and XmAb the antibody half-life data shots have nature generate allows to to portability suite engineer and to guide, flexibility plug programs created structure. to will longer us which we've goal advance independently enable play any multiple of take This bispecific potency, partner on and proof-of-concept of or or Fc or domains improved terminate.
few bispecific and or Now, XXXX, bispecific two use expansion focused XmAb the we've antibodies. drug in to new studies efforts Phase the past clinical simultaneously. targets create years, on different of Since XmAb X R&D our initiated evaluating we that platform candidates our bind more six
rapid Our to play development enables plug antibodies cytokines. approach engineering other the and like structures of design and and protein simplified
Fc therapeutic heterodimeric the area we cell at group Bispecifics into very engineered T of forefront space, order and bispecifics, we a domain and tumor in develop bispecifics this different candidates activator scaffold robust development, three use engager as microenvironment rapidly are to rapidly our to of cytokines. on oncology classes; emerging in innovation new stay particularly that
tumor These engager at class antigen kill CDX tumor specifically contain the tumor cells. binding site domain bispecifics They binding targeted and order that most is the the the in to of first and cells advanced T T-cell antibodies class. both potently domain. cell So, cytotoxic activate domain the T binding are a malignant
relapsed our -- X label XmAbXXXXX malignancies. partner, or being that's preliminary tolerability escalation in open study activity antitumor CDX hematologic safety, acute well as leukemia, assess Phase antibody refractory Novartis. being expressing is patients CDXXX by an developed and as with It's in myeloid our dose is other in bispecific to developed with CDXXX collaboration
clinical prescriptive guidance monitoring cytokine lifting following protocol, hold. included the release more under study a and management amended which partial of syndrome restarted In the second quarter, the the of on we an
planning internal are We study continue dose evaluating clinical escalation XmAbXXXXX in XXXX. studies and the in
program malignancies Phase B-cell and in with non-Hodgkin X, a next for chronic advanced lymphoma but XmAbXXXXX, CDX Our patients also by like It's CDXX antibody. lymphocytic bispecific is leukemia.
where We and expect the That's to dose present clinical data show December, Meeting we in ASH escalation activity. safety initial to plan study this from during at cohorts. Annual
cell Now bispecific. an or XmAbXXXXX is It highly our X, on third engaging solid SSTRX antigen Receptor tumors. T Somatostatin CDX targets expressed some
In tumors study anti-tumor preliminary with early we its and started dosing a escalation gastrointestinal patients assess tolerability Phase dose stromal XXXX, in neuroendocrine and patients X in activity tumors. to safety,
half that from study XXXX. expect present to We first of in initial data the
Now our Activators. activators reactive than a Tumor effectively cell, Rather TME bispecific do. through cytotoxic seek tumor than cell bridging our to our more cells of next therapies Microenvironment antibodies tumor reactivate T existing group directly is a T
up on antibodies with engage a key targets multiple surface, Our is binding feature for choose present. zipping agonists, is checkpoints each targets two cell cells and T one the be binding such target individual only design as present their to when suboptimal when binding or or antibody simultaneously for hand-holds T of affinities have called are multiple for its T to of the This but both targets avidity. to high cell
for for periphery. of used that cells have T microenvironment need selective And in multiple checkpoint more often in the the tumor multiple than typically in therapy. antibodies more These targeting reduces typically approach found expression. combination Our the also are allows
XXXXX X second dosing focused tumor in we're of these we Phase ongoing Phase earlier on enrolling with first third dose Now of several studies along XXXXX, clinical started solid studies. year, trials, patients and XmAbXXXXX, the with types our patients XmAbs and X advanced escalation in the study TME this
in PD-X by first initial patients. Our half XXXX. of these hope is tolerability anti-tumor to programs dose bispecific CTLA-X XmAbXXXXX responses We be drive first stronger anticipate for our to of able for the escalation data in the biomarker improved with
of Xtend cytokine -- that the that top immune also Fc proteins incorporate bispecific Finally, domain are These domain. built a in XmAb our developing suite signaling our of we're immune cytokines. technology on Fc we've and
be made druggable potentially with tolerability, and mediated to Fc tuning slower cytokines molecules prolonged Using domain enables and this potencies receptor these of the superior half-life. more clearance
bispecific with the an and It's collaboration on are Fc domain. program subunit our Genentech cytokine and in those . XmAbXXXXX of fused is first our both IL-XX its receptor-alpha with fused lead Our
cytokine and it contains to its activate natural T noted, and both cells As in and domain expand order killer receptor cells. the
for wide a this is trials our own agents, these both combination the own of subject with to initial importantly, perform range conditions. dose collaboration, non-Genentech pending development look can clinical number combination pipeline of with XmAbXXXXX studies study. within a our completion and escalation we We planning intended and agents of some forward to assets
next are first dosing indications study in IND Currently, expected anticipate before Genentech's a year, which patients year. is we we end human multiple oncology supporting early this application, of the in
candidates from very switch to product, going in updates which each stage four results continue of clinical reviewing to but have us. one our and resources to which two effort not We're our initiations. from open fund licensing we pipeline program, partnerships have some require of helps review technology, internal X INDs partnerships, revenue pending provide marketed ongoing candidates these and limited XmAb eight Most for and now own partnerships candidates. that We'll development Phase
improved to by allows with marketed frequent technology be used complement to In XXXX, inhibitor Soliris. Fc with excited less regimens incorporate which Alexion, Ultomiris. we're and creating It's first in we compared licensed for Xtend antibody which the very was XmAb that. Their half-life, an dosing technology to
worldwide. approval FDA geographies PNH, Japan received sales Europe the and has the and aHUS. of all uremic adults now Ultomiris indications royalty syndrome with treatment received month Ultomiris the for on global net with the and in patients receiving a from of last multiple U.S., X.X% marketing atypical treatment for or hemolytic authorizations We're on
It's they Another update anti-CD licensed range reaffirmed Fc domain payments. the is this an we MORXXX end partner MorphoSys in from designed to double-digit XX as approved, that tafasitamab BLA last that function. antibody that was week which for ADCC as developed and well high-single our of we initially XmAbXXXX. previously additional us known to receive high incorporating and intend complete before a MorphoSys as submission low call percentage the on year. royalties If milestone their by cytotoxic
Recently, we creation by uses X bispecific FDA that by AMG for undisclosed other IND of Novartis and XXXX, by advanced XmAb bispecific would allowed STEAPX research partners. collaborations that Amgen's novel plus included applications the entered X XmAb format. antibodies that CDX and and a Amgen into an these XXXX bispecific the be for of with among antibody Novartis terms them antibody our Between XmAb were XXX,
of That tumor recognize This domain. format uses other candidates Fc in of quarter. targeting all it the revenue milestone cells. but total, targeting our for we domains has third In same tumor collaborations two as from these $XX higher domain the heterodimeric selectivity antigen expressing CDX XmAb one format and million allows
years as and law we has have Corporate past Corporate Finally, announced to in we Celia Attorney This team. our Secretary. in-house General Eckert than rules. the senior management firms more XX spent as and expand Counsel quarter, appointment of Celia both a continued
building as an in strong a of matures instrumental is absolutely organization our through thrilled advances, legal which the portfolio programs to We're and clinical and required have be stages the Xencor later development. on Celia team. infrastructure grows She'll as
John Now review our XXXX the quarter to call with over Kuch to turn that, I'll financials. third
